查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600112

免疫疗法药物市场：按类型、应用和最终用户划分 - 全球预测 2025-2030

Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy), Application (Autoimmune Disease, Infectious Disease, Neurology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年免疫疗法药物市场价值为1756.4亿美元，预计2024年将达到1969.6亿美元，复合年增长率为12.35%，预计到2030年将达到3970.2亿美元。

免疫疗法药物 免疫疗法是製药业中一个强大且不断发展的部分，旨在增强或改变免疫系统对抗癌症、感染疾病和其他疾病的能力。免疫疗法的需求在于其能够更精确地靶向特定细胞，可能比化疗等传统治疗方法产生更少的副作用。这些治疗剂具有广泛的用途，包括肿瘤学、感染疾病管理、自体免疫疾病和过敏治疗。最终用途主要是医院、癌症研究机构和专科诊所。重要的成长要素包括生物技术的进步、癌症和慢性病盛行率的上升以及研发资金的增加。个人化医疗和联合治疗存在关键机会，可以提高治疗效果并减少治疗抵抗。也建议采用数位健康技术并与生物技术公司合作进行药物共同开发，以开发潜在的市场机会。然而，高昂的开发成本、严格的监管核准以及免疫反应的复杂性等挑战使市场扩张变得复杂。智慧财产权问题和对其长期影响的有限理解进一步阻碍了进展。创新可以集中于开发生物标记以更好地对患者进行分层，改善递送机制以提高药物稳定性和疗效，以及扩大现有药物的适应症。继续研究了解肿瘤微环境和免疫景观仍然至关重要。该市场的特点是技术进步迅速、製药巨头之间竞争激烈、战略联盟和併购数量不断增加。总体而言，该领域的相关人员需要对新的科学发现保持警惕，对技术整合保持灵活性，并投资创新的临床试验，以充分发挥免疫疗法的潜力。

主要市场统计
基准年[2023] 1756.4亿美元
预测年份 [2024] 1969.6亿美元
预测年份 [2030] 3970.2亿美元
复合年增长率（%） 12.35%

市场动态：揭示快速发展的免疫治疗市场的关键市场洞察

供需的动态交互作用正在改变免疫治疗药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球慢性病盛行率上升
    • 新免疫治疗药物的核准和上市增加
    • 消费者对个人化医疗的需求不断增长
  • 市场限制因素
    • 核准流程复杂且漫长
  • 市场机会
    • 政府更重视开发先进的免疫疗法药物
    • 私人公司和新兴生物企业的投资增加
  • 市场挑战
    • 关于药物副作用的安全性担忧日益增加

波特五力：驾驭免疫治疗药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解免疫治疗市场的外部影响

外部宏观环境因素在塑造免疫治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解免疫治疗药物市场的竞争格局

免疫疗法药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵免疫疗法药物市场供应商的绩效评估

FPNV定位矩阵是评估免疫疗法药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划免疫治疗药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，免疫治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界慢性病的增加
      • 新免疫治疗药物的核准和上市增加
      • 消费者对个人化医疗的需求增加
    • 抑制因素
      • 核准流程复杂且漫长
    • 机会
      • 各国政府越来越注重开发先进技术
      • 私营部门和新兴生物技术Start-Ups的投资增加
    • 任务
      • 对药物副作用的安全性疑虑日益增加
  • 市场区隔分析
    • 类型：癌症疫苗需求随着癌症发生率的增加而增加
    • 应用：自体免疫疾病治疗的新应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章免疫治疗药物市场：依类型

  • 癌症疫苗
  • 查核点抑制剂
  • 细胞激素治疗
  • 单株抗体
  • T细胞疗法

第七章免疫治疗药物市场：依应用分类

  • 自体免疫疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学

第八章免疫治疗药物市场：依最终用户分类

  • 医院
  • 专科诊所

第九章美洲免疫治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太免疫治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲免疫疗法药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Hanmi Pharmaceutical 与默克合作开创晚期癌症治疗的协同免疫疗法
    • Pathios Therapeutics 已获得 2500 万美元的 B 轮融资，以推进免疫治疗临床试验并推动长期肿瘤学创新。
    • 辉瑞收购 Seagen 是为了利用先进的 ADC 技术加速创新癌症治疗，加强其在肿瘤学领域的领导地位并扩大其全球影响力。
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Affimed Therapeutics
  • AstraZeneca PLC
  • Atara Biotherapeutics
  • Biogen Inc.
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics
  • Celldex Therapeutics
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • ElevateBio
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Turnstone Biologics
Product Code: MRR-521BAA36EBB6

The Immunotherapy Drugs Market was valued at USD 175.64 billion in 2023, expected to reach USD 196.96 billion in 2024, and is projected to grow at a CAGR of 12.35%, to USD 397.02 billion by 2030.

Immunotherapy drugs, a potent and evolving segment in the pharmaceutical industry, are designed to enhance or modify the immune system's ability to fight cancer, infectious diseases, and other disorders. The necessity of immunotherapy lies in its ability to target specific cells more precisely, offering potentially fewer side effects compared to traditional therapies like chemotherapy. Applications of these drugs span oncology, infectious disease management, autoimmune disorders, and allergy treatment. End-use is primarily within hospitals, cancer research institutions, and specialty clinics. Critical growth factors include advancements in biotechnology, rising prevalence of cancer and chronic diseases, and increased funding for research and development. Key opportunities exist in personalized medicine and combination therapies, which can enhance the efficacy and reduce resistance to treatment. Embracing digital health technologies and conducting collaborations for co-developing drugs with biotech firms are also recommended strategies for harnessing potential market opportunities. However, challenges such as high development costs, stringent regulatory approvals, and the complexity of immune responses complicate market expansion. Intellectual property issues and limited understanding of long-term effects further hinder progress. Innovation can be focused on the development of biomarkers for better patient stratification, improving delivery mechanisms to enhance drug stability and effectiveness, and expanding indications for existing drugs. Continuous research into understanding tumor microenvironments and immune landscapes remain pivotal. The market is characterized by rapid technological advancements, high competition among pharmaceutical giants, and an increasing number of strategic partnerships and mergers. Overall, stakeholders in the field should stay vigilant to emerging scientific discoveries, adapt flexibly to technological integrations, and invest in innovative clinical trials to optimize immunotherapy's full potential.

KEY MARKET STATISTICS
Base Year [2023] USD 175.64 billion
Estimated Year [2024] USD 196.96 billion
Forecast Year [2030] USD 397.02 billion
CAGR (%) 12.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunotherapy Drugs Market

The Immunotherapy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • The rising incidence of chronic diseases globally
    • Increasing approval and launch of new immunotherapy drugs
    • Growing demand for personalized medicine among consumers
  • Market Restraints
    • Complex and lengthy approval processes
  • Market Opportunities
    • Growing government emphasis on development of advanced immunotherapy drugs
    • Rising investments from private sectors and emerging biotech startups
  • Market Challenges
    • Emerging safety concerns of side effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Immunotherapy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunotherapy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunotherapy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunotherapy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunotherapy Drugs Market

A detailed market share analysis in the Immunotherapy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunotherapy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunotherapy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunotherapy Drugs Market

A strategic analysis of the Immunotherapy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunotherapy Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Affimed Therapeutics, AstraZeneca PLC, Atara Biotherapeutics, Biogen Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celldex Therapeutics, Cipla Ltd., Dr. Reddy's Laboratories Ltd., ElevateBio, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Samyang Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Turnstone Biologics.

Market Segmentation & Coverage

This research report categorizes the Immunotherapy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cancer Vaccines, Checkpoint Inhibitors, Cytokines-Based Therapy, Monoclonal Antibodies, and T-cell Therapy.
  • Based on Application, market is studied across Autoimmune Disease, Infectious Disease, Neurology, and Oncology.
  • Based on End-User, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising incidence of chronic diseases globally
      • 5.1.1.2. Increasing approval and launch of new immunotherapy drugs
      • 5.1.1.3. Growing demand for personalized medicine among consumers
    • 5.1.2. Restraints
      • 5.1.2.1. Complex and lengthy approval processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing government emphasis on development of advanced immunotherapy drugs
      • 5.1.3.2. Rising investments from private sectors and emerging biotech startups
    • 5.1.4. Challenges
      • 5.1.4.1. Emerging safety concerns of side effects of drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing demand for cancer vaccines with the rising prevalence of cancer
    • 5.2.2. Application: Emerging application for autoimmune disease therapy
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Immunotherapy Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Cancer Vaccines
  • 6.3. Checkpoint Inhibitors
  • 6.4. Cytokines-Based Therapy
  • 6.5. Monoclonal Antibodies
  • 6.6. T-cell Therapy

7. Immunotherapy Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Disease
  • 7.3. Infectious Disease
  • 7.4. Neurology
  • 7.5. Oncology

8. Immunotherapy Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics

9. Americas Immunotherapy Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Immunotherapy Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Immunotherapy Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Hanmi Pharmaceutical and Merck forge partnership to pioneer synergistic immunotherapy for advanced cancer treatment
    • 12.3.2. Pathios Therapeutics secures USD 25 Million in series B to propel immunotherapy treatments into clinical trials and drive long-term oncology innovations
    • 12.3.3. Pfizer acquires Seagen to accelerate innovative cancer therapies with advanced ADC technology, strengthening leadership in oncology and expanding global impact
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Affimed Therapeutics
  • 3. AstraZeneca PLC
  • 4. Atara Biotherapeutics
  • 5. Biogen Inc.
  • 6. Boston Scientific Corporation
  • 7. Bristol-Myers Squibb Company
  • 8. CARsgen Therapeutics
  • 9. Celldex Therapeutics
  • 10. Cipla Ltd.
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. ElevateBio
  • 13. F. Hoffmann-La Roche AG
  • 14. Gilead Sciences, Inc.
  • 15. GlaxoSmithKline PLC
  • 16. Johnson & Johnson Services, Inc.
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Samyang Holdings Corporation
  • 22. Sanofi S.A.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Turnstone Biologics

LIST OF FIGURES

  • FIGURE 1. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IMMUNOTHERAPY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023